Genistein Mediated Regulation of Prostate Cell Adhesion

Raymond Bergan, MD and William Catalona, MD

The study has been taking place at Northwestern University, in Chicago, Illinois. Although this study is closed to accrual, another similar study will be opening soon. If you are interested in the study, have any questions, or want more information, please call me at: 312-908-5284 . I will return your call as soon as I can.

Raymond Bergan, MD

Effect of Dutasteride on Androgen-Response Gene Expression During the Tumor Regrowth Phase of Intermittent Androgen Ablation Therapy in Patients with Advanced Prostate Cancer

Zhou Wang, Ph.D. and Daniel Shevrin, M.D.

Intermittent androgen ablation therapy is frequently used as initial treatment for patients with advanced prostate cancer. We have demonstrated in the laboratory that certain androgen-response genes are overexpressed during the off-cycle (regrowth phase) of intermittent androgen treatment. We also have shown that testosterone is more potent in inducing these tumor suppressor genes than dihydrotestoesterone. Further, a 5a-reductase inhibitor given during the regrowth phase prolonged this time period and prolonged survival in test animals. We have designed a clinical trial to test the effect of dutasteride on the expression of a specific tumor suppressor androgen-response gene - U19. The purpose of this study is to find out if adding the drug dutasteride (Avodart) to androgen ablation therapy can improve treatment for prostate cancer. Another purpose of this study is to determine if the use of dutasteride slows the rise of blood PSA (Prostate Specific Antigen) during the "rest" cycles. It is known that PSA levels reflect tumor growth.

If you are interested in this study, have any questions, or want more information, please contact Dr. Shevrin at 847-570-2515 dshevrin@northshore.org or our Study Coordinator Kat Schwartz, MS at 847-570-4193 kschwartz@northshore.org or Dr. Gary MacVicar at 312-695-0990 g-macvicar@northwestern.edu.

Previous Page